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Background: Neuropathic pain is characterized by hypersensitivity to innocuous stimuli (tactile allodynia) that is
nearly always resistant to NSAIDs or even opioids. Gabapentin, a GABA analogue, was originally developed to treat
epilepsy. Accumulating clinical evidence supports the effectiveness of this drug for diverse neuropathic pain. In this
study, we showed that the anti-allodynic effect of gabapentin was changed by the circadian oscillation in the
expression of its target molecule, the calcium channel a2δ-1 subunit.
Results: Mice were underwent partial sciatic nerve ligation (PSL) to create a model of neuropathic pain. The paw
withdrawal threshold (PWT) in PSL mice significantly decreased and fluctuated with a period length about 24 h.
The PWT in PSL mice was dose-dependently increased by intraperitoneal injection of gabapentin, but the anti-
allodynic effects varied according to its dosing time. The protein levels of a2δ-1 subunit were up-regulated in the
DRG of PSL mice, but the protein levels oscillated in a circadian time-dependent manner. The time-dependent
oscillation of a2δ-1 subunit protein correlated with fluctuations in the maximal binding capacity of gabapentin.
The anti-allodynic effect of gabapentin was attenuated at the times of the day when a2δ-1 subunit protein was
abundant.
Conclusions: These findings suggest that the dosing time-dependent difference in the anti-allodynic effects of
gabapentin is attributable to the circadian oscillation of a2δ-1 subunit expression in the DRG and indicate that the
optimizing its dosing schedule helps to achieve rational pharmacotherapy for neuropathic pain.
Background
Neuropathic pain is a chronic condition that occurs
after bone compression in cancer, diabetes, herpesvirus
infection and auto immune disease [1]. Millions of
patients in the world presently endure neuropathic pain
[2]. One troublesome hallmark symptom of neuropathic
pain is hypersensitivity to normally innocuous stimuli, a
condition known as “tactile allodynia” that is often
refractory to NSAIDs and opioids [3].
The GABA analogue gabapentin was originally devel-
oped to treat epilepsy [4], but it is now widely used to
alleviate neuropathic pain [3]. Accumulating evidence
from diverse animal models of neuropathic pain suggests
that the anti-allodynic effects of gabapentin are asso-
ciated with the modulation of neurotransmitter release or
neuronal excitability resulting from alterations in Ca
2+
currents [5,6]. The a2δ subunit, but not the pore-forming
a1o rb subunits, of voltage-dependent Ca
2+ channels
(VDCC) in the spinal cord and dorsal root ganglion
(DRG) is upregulated in gabapentin-sensitive pain models
such as mechanical- and diabetic-neuropathic types, but
not in the gabapentin-insensitive chemical model of neu-
ropathic pain [7-9]. The timec o u r s eo fu p r e g u l a t i o no f
the a2δ subunit in DRG is parallel to the duration of
neuropathic pain induced by nerve injury [9]. Gabapentin
is thought to modulate Ca
2+ currents by binding to the
a2δ-1 subunit of VDCC [10-12].
Gabapentin is now widely used to alleviate neuro-
pathic pain because it is well-tolerated, easily titrated,
and has interacts with few drugs [13]. However, higher
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ness, drowsiness, and peripheral edema [14]. The appro-
priate dosing schedule of gabapentin has not been
well-established yet.
One approach to increasing the effect of pharma-
cotherapy is to administer drugs at the times of day
when they are most effective and/or best tolerated. Cir-
cadian variations in biological functions such as gene
expression and protein synthesis are thought to be
important factors affecting the efficacy of drugs. In fact,
the expression levels of proteins related to the regula-
tion of the susceptibility to the drugs and their pharma-
cokinetics oscillated in a circadian time-dependent
manner [15-17]. It is thus possible that the pharmacolo-
gical effects of gabapentin could be more improved by
choosing the appropriate dosing time. To test this possi-
bility, we explored whether the anti-allodynic effects of
gabapentin in a mouse model of neuropathic pain
was changed according to its dosing time. The mechan-
ism underlying dosing time-dependent changes in
the anti-allodynic effects of gabapentin was investigated
from the perspectives of pharmacokinetics and
pharmacodynamics.
Results
Time-dependent changes in allodynic behavior of mice
To create an animal model of neuropathic pain, we pre-
pared mice undergone partial sciatic nerve ligation
(PSL). As reported previously [18], the paw withdrawal
threshold (PWT) of PSL mice significantly decreased
after nerve injury (P < 0.05; Figure 1A). The decrease in
PWT continued until at least 3 weeks (data not shown).
On day 7 after nerve injury, the PWT in PSL mice sig-
nificantly varied over 24 h, with trough levels persisting
from the late light phase, to the early dark phase (P <
0.05; Figure 1B). The time-dependent difference of PWT
of PSL mice began to be observed on day 5 after nerve
injury. On the other hand, PWT in sham-operated mice
did not significantly change time-dependently.
Influence of dosing-time on anti-allodynic effects of
gabapentin in PSL mice
On day 7 after nerve injury, PSL mice were injected
intraperitoneally (i.p.) with 50, 100, and 150 mg/kg of
gabapentin or saline at 17:00. A single injection of gaba-
pentin transiently and dose-dependently increased the
PWT of PSL mice (Figure 2A). The PWT reached a
peak level around 1 h after gabapentin injection and
declined to the basal level within 4 h. A significant
attenuation of tactile allodynia was found at the dosage
of gabapentin over 100 mg/kg.
We next investigated whether the anti-allodynic effects
of gabapentin varied according to dosing time. On day 7
after nerve injury, PSL mice were injected i.p. with 100
mg/kg of gabapentin at 17:00 or 5:00. These time points
were selected based on the peaks and troughs of the
allodynic behavior of PSL mice when not administered
with the drug (Figure 1B). Although the PWT of PSL
mice was transiently increased after gabapentin injection
at both time points (Figure 2B left panel), the PWT was
much higher in mice injected with gabapentin at 5:00
than at 17:00. Consequently, the area under the curve
(AUC) of the PWT after gabapentin injection at 5:00
was also larger than that after the drug injection at
17:00 (p < 0.05, Figure 2B right panel).
By normalizing the basal level of PWT, the anti-allo-
dynic effect of gabapentin was also compared between
the two time points. At 2, 3, and 4 h after gabapentin
i n j e c t i o n ,t h eP W To fP S Lm i c ew e r eh i g h e ra t5 : 0 0
than at 17:00 (Figure 2C left panel). A significant dos-
ing time-dependent difference in the PWT of PSL
mice was observed at 3 hr after gabapentin injection (p
< 0.05). Furthermore, normalized AUC of the withdra-
wal threshold after gabapentin injection at 5:00 tended
Figure 1 Time-dependent variation in PWT of PSL mice.( A )
Time course of PWT of PSL and sham operated mice after nerve
injury. Values are shown as means with S.E.M. (n = 6). *P < 0.05
compared with sham group at corresponding time points. (B)
Variation in PWT over 24 h in PSL and sham-operated mice on day
7 after nerve injury. Values are shown as means with S.E.M. (n = 12).
The PWT in PSL, but not in sham operated mice, significantly varied
over 24 h (P < 0.05; ANOVA).
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tion at 17:00 (p = 0.09, Figure 2C right panel). These
results suggest that the anti-allodynic effect of gaba-
pentin was varied according to its dosing time. The
dosage of gabapentin more significantly alleviated tac-
tile allodynia in PSL mice at 5:00 than at 17:00. The
difference in the dosing time-dependent anti-allodynic
effects of gabapentin seemed not to be associated with
sedation because the mouse locomotor activities were
not significantly suppressed by 100 mg/kg gabapentin
(Additional file 1).
Influence of dosing time on the gabapentin
pharmacokinetics
To determine the underlying mechanism of the dosing
time-dependent difference in the anti-allodynic effects
of gabapentin, we measured serum concentrations of
gabapentin in PSL mice on day 7 after nerve injury.
The serum levels peaked within 1 h after gabapentin
injection (100 mg/kg, i.p.) and then biphasically decayed
(Figure 3). However, the serum gabapentin concentra-
tion did not significantly differ between the two dosing
times.
Gabapentin is incorporated into cells via the L-amino
acid transporter and it acts on the a2δ-1 subunit of
VDCC to modulate Ca
2+ currents [12]. Because the L-
amino acid transporter is expressed in the DRG neuron
(Additional file 2), we further investigated whether gaba-
pentin incorporation into L4/L5 DRG varied time-depen-
dently. On day 7 after nerve injury, contralateral or
ipsilateral DRG isolated from PSL mice were incubated
with various concentrations of [
3H]-gabapentin for 30
min. The incorporation of [
3H]-gabapentin into the iso-
lated DRG was concentration-dependent when the seg-
ments were incubated with the drug at 37°C (Figure 4A
left panel). This process seemed to be energy-dependent
because the amount of [
3H]-gabapentin incorporation
was significantly decreased by incubating the DRG at 4°C
(Figure 4A right panel). However, the amount of [
3H]-
gabapentin incorporated into both the contralateral and
ipsilateral DRG did not significantly differ between the
two dosing times when the segments were incubated
with 100 or 500 μM gabapentin (Figure 4B).
Figure 2 Influence of dosing-time on the anti-allodynic effects
of gabapentin in PSL mice. (A) Time course of PWT in PSL mice
after i.p. injection with 50, 100 and 150 mg/kg gabapentin or saline
on day 7 after nerve injury. Values are shown as means with S.E.M.
(n = 6). *P < 0.05 compared with saline-treated group. (B) Dosing
time-dependence of anti-allodynic effects of gabapentin in PSL
mice. Gabapentin (100 mg/kg, i.p.) was injected into PSL mice at
17:00 or 5:00. The AUC of PWT after gabapentin injection was
calculated using trapezoidal rule. Values are shown as means with S.
E.M. (n = 6). In left panel, *P < 0.05 compared with 17:00 group at
corresponding dosing time. In right panel, *P < 0.05 compared
between two groups. (C) Comparison of normalized PWT (left) and
AUC (right) after gabapentin (100 mg/kg, i.p.) injection. *P < 0.05
compared with 17:00 group at corresponding dosing time.
Figure 3 Influence of dosing time on serum concentration of
gabapentin in PSL mice. Gabapentin (100 mg/kg) was
administered i.p. at 17:00 or 5:00 on day 7 after nerve injury. Values
are shown as means with S.E.M. (n = 5-6). Serum concentrations of
gabapentin were measured by HPLC using fluorescence detection.
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3H]-gabapentin binding in the
ipsilateral DRG
On day 7 after nerve injury, we estimated the binding
parameters of gabapentin in L4/L5 DRG of PSL mice.
T h ea m o u n to fs p e c i f i cb i n d i n go f[
3H]-gabapentin
(Bspecific) in the ipsilateral DRG was larger than that in
the contralateral DRG. Furthermore, the specific binding
of [
3H]-gabapentin in the ipsilateral DRG significantly
varied in a time-dependent manner (P < 0.05; Figure
5A); a large amount of [
3H]-gabapentin bound at 17:00.
In contrast, the amount of [
3H]-gabapentin binding in
the contralateral DRG did not significantly vary time-
dependently. Scatchard plot analysis revealed that the
maximal binding capacity (Bmax)f o r[
3H]-gabapentin in
the ipsilateral DRG was significantly larger at 17:00 than
at 5:00 (p < 0.05; Figure 5B left panel), whereas the
affinity constants (Kd) value did not differ significantly
between ipsilateral DRG prepared at 17:00 and 5:00
(Figure 5B right panel).
Time-dependent oscillation in the expression of a2δ-1
subunit in the ipsilateral DRG
On day 7 after nerve ligation, protein levels of a2δ-1
subunit of VDCC in the ipsilateral DRG substantially
increased in response to nerve injury, but the levels fluc-
tuated rhythmically in a circadian fashion (Figure 6A).
The rhythmic phase of a2δ-1 protein levels was almost
identical to the oscillation of maximal [
3H]-gabapentin
binding capacity (Bmax) of the ipsilateral DRG (Figure
5B). The mRNA levels of the a2δ-1 subunit also
increased in the ipsilateral DRG of PSL mice and signifi-
cantly oscillated over 24 h (Figure 6B, left panel). By
contrast, the mRNA levels of other pore-forming subu-
nits of VDCC, namely the a1A subunit did not signifi-
cantly vary over 24 h (Figure 6B, right panel).
Taken together, these results suggest that the maximal
[
3H]-gabapentin binding capacity (Bmax) in the ipsilateral
Figure 4 Incorporation of [
3H]-gabapentin into DRG of PSL
mice is not changed time dependently. (A) Left and right panels
show concentration and temperature dependence of [
3H]-
gabapentin incorporation by ipsilateral DRG, respectively. Segments
of ipsilateral DRG prepared from PLS mice were incubated for 30
min at 37°C or 4°C with Krebs-Henseleit buffer containing indicated
concentrations of [
3H]-gabapentin. Values are shown as means with
S.E.M. (n = 3). (B) Contralateral (left) and ipsilateral (right) DRG
prepared from PLS mice at 17:00 or 5:00 were incubated with
Krebs-Henseleit buffer containing indicated concentrations of [
3H]-
gabapentin for 30 min at 37°C. Each value represents the mean
with S.E.M. (n = 3).
Figure 5 Time-dependent [
3H]-gabapentin binding in DRG of
PSL mice. (A) Concentration dependence of [
3H]-gabapentin
binding to soluble fraction of contralateral and ipsilateral DRG.
Segments of DRG were prepared at 17:00 and 5:00. Values are
shown as means with S.E.M. (n = 3). (B) Estimated maximum
binding capacity (Bmax)o f[
3H]-gabapentin to soluble fraction of
DRG of PSL mice and its affinity constants (Kd). Values are shown as
means with S.E.M. (n = 3). *P < 0.05 compared between two
groups.
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a2δ-1 protein abundance. There was no significant
time-dependent variation in the gabapentin incorpora-
tion into the ipsilateral DRG (Figure 4B). If the same
amount of gabapentin could bind to a2δ-1 subunit at
17:00 and at 5:00, the occupancy of gabapentin binding
sites in a2δ-1 in the ipsilateral DRG of PSL mice would
be 2-fold higher at 5:00 than at 17:00.
Discussion
Because the risk and/or intensity of disease symptoms
vary during the day, many drugs should not be equally
potent at different administration times. For example,
the frequency of asthmatic episodes increases from
midnight until the early morning, because of night
time increases in airway potency, bronchial responsive-
ness and the release of inflammatory factors [19].
Therefore, evening dosing with theophylline produces
a significant improvement in nocturnal asthmatic
symptoms [20]. Evening dosing with H2 receptor
antagonists is more effective for treating peptic ulcers
because gastric secretion increases from evening to
night [21]. A significant time-dependent variation has
been identified in rheumatic and/or osteoarthritic pain
[22,23]. Furthermore, the intensity of pain in patients
with diabetic neuropathy or post-herpetic neuralgia
also varies over 24 h [24]. However, chronopharmaco-
logical strategy has not been applied to the treatment
of patients with neuropathic pain. Here, we found that
the PWT in PSL mice significantly varied over 24 h;
allodynic behavior was more severe from the late light,
to the early dark phase. Rhythmic changes in allodynic
pain among PSL mice seemed to be associated with
dosing time-dependent differences in the anti-allodynic
effects of gabapentin.
Both the sensitivity of living organisms to drugs and
their pharmacokinetics influence drug effectiveness
[25,26]. An i.p. injection of 100 mg/kg into PSL mice at
17:00 or 5:00 did not elicit significant dosing time-
dependent differences in the serum concentration of
gabapentin. Gabapentin is well absorbed orally, circu-
lates unbound to plasma protein and it is excreted
mostly in an unaltered form into urine [13]. The L-
amino acid transporter is responsible for the intracellu-
lar uptake of gabapentin [27], which allows influxed
gabapentin to act on its target in neurons. However,
gabapentin incorporation into the ipsilateral DRG neu-
rons did not significantly differ between the two dosing
times. This may be explained partly by the arrhythmic
expression of L-amino acid transporter-1 gene in the
ipsilateral DRG (Additional file 2). Taken together, these
results suggest that gabapentin pharmacokinetics do not
principally contribute to the dosing time-dependent
changes in its anti-allodynic action.
Although several mechanisms have been suggested for
the anti-allodynic effects of gabapentin, the a2δ subunit
of VDCC comprise the most attractive candidates as tar-
gets. The expression of a2δ subunit is up-regulated in
the spinal cord and DRG of gabapentin-sensitive, but
not gabapentin-insensitive neuropathic pain models [8].
Four a2δ subunits (a2δ-1, a2δ-2, a2δ-3, and a2δ-4)
have been identified [28,29]. Primary sequence compari-
sons suggest that a2δ-3 and a2δ-4 lack the gabapentin
binding motifs characterized for a2δ-1 and a2δ-2
[28,30]. Gabapentin has higher affinity for a2δ-1, than
a2δ-2 subunits [28,30]. The protein levels of a2δ-1 sub-
unit in the ipsilateral DRG of PSL mice were increased
after nerve injury, but rhythmically fluctuated in a time-
dependent manner. The mRNA levels of a2δ-1 in the
ipsilateral DRG also exhibited a circadian oscillation,
and the rhythmic phase of a2δ-1 mRNA expression was
similar to that of its protein abundance. The circadian
clock genes, the molecular components of the clock-
work, regulate the expression of their target molecules
at the transcription level [25,26]. The mRNA levels of
A 
B 
09 13 17 21 01 05 











































09 13 17 21 01 05 09 13 17 21 01 05 
Sampling time (Clock hours) 
Sampling time (Clock hours) 



































Contralateral  Ipsilateral 
Contralateral








































Figure 6 Expression of a2δ-1 in DRG of PSL mice varies over
24 h. (A) Temporal expression profile for a2δ-1 protein in
contralateral and ipsilateral DRG of PSL mice. Values are normalized
by protein levels of ACTIN. Values are shown as means with S.E.M.
(n = 3). *P < 0.05 compared with contralateral side at
corresponding time points. Levels of a2δ-1 protein significantly
varied over 24 h in ipsilateral DRG (P < 0.05; ANOVA). Left panel
shows representative western blots of a2δ-1 protein in contralateral
and ipsilateral DRG of PSL mice. (B) Temporal expression profile of
a2δ-1 (left) and a1A (right) mRNA in contralateral and ipsilateral
DRG of PSL mice. Values are shown as means with S.E.M. (n = 4-6).
*P < 0.05 compared with contralateral side at corresponding time
points. Levels of a2δ-1 mRNA significantly varied over 24 h in
ipsilateral DRG (P < 0.05; ANOVA).
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in a circadian-dependent manner (data not shown), indi-
cating that the ipsilateral DRG has a normal clock func-
tion. Consequently, the oscillation in the expression of
a2δ-1 in PSL mice is generated at the transcriptional
level, which is controlled by the molecular organization
of the circadian clockwork. Protein levels of a2δ-1 subu-
nit in the DRG significantly correlate with the duration
of neuropathic pain induced by nerve injury [7,9]. In
fact, transgenic mice overexpressing the a2δ-1 subunit
are hypersensitive to mechanical and thermal stimuli
[31]. Therefore, oscillation of a2δ-1 subunit expression
in the ipsilateral DRG might underlie the time-depen-
dent change in the allodynic behavior of PSL mice.
The anti-allodynic effect of gabapentin was attenuated
at the times of the day when a2δ-1 subunit protein was
abundant. The amount of [
3H]-gabapentin binding in
the DRG was correlated with the protein levels of a2δ-1
subunit (Additional file 3), suggesting that the time-
dependent change in the specific binding of [
3H]-gaba-
pentin is due to the oscillation in the expression of a2δ-
1 protein. Consequently, scatchard plot analysis also
revealed that the maximal binding capacity of gabapen-
tin (Bmax) in the ipsilateral DRG varied significantly in a
time-dependent manner. The maximal binding capacity
of gabapentin was about 2-fold higher at 17:00 than at
5:00. On the other hand, the amounts of gabapentin
incorporation into the ipsilateral DRG did not signifi-
cantly differ between the two dosing times. If the same
amount of gabapentin bound to a2δ-1 protein at 17:00
and at 5:00, the occupancy of gabapentin binding sites
in a2δ-1 protein at 5:00 would be estimated 2-fold
higher than that at 17:00. Therefore, the anti-allodynic
effects of gabapentin may be enhanced by injection with
the drug at 05:00. This would account for the dosing
time-dependent change in the gabapentin-induced anti-
allodynic effects.
Conclusions
The present findings in this animal model help to clarify
how the anti-allodynic effects of gabapentin vary accord-
ing to dosing time. The intensity of neuropathic pain
also changes time-dependently in patients with diabetic
neuropathy and post-herpetic neuralgia [24], indicating
that an appropriate dosing regimen is needed to treat
such chronic pain. Our results suggest that the thera-
peutic efficacy of gabapentin on neuropathic pain could
be improved by optimizing the dosing schedule.
Materials and methods
Animals and treatments
Five-week-old male ICR mice (Charles River Japan) were
housed in groups of 6 or 10 per cage in a light-con-
trolled room (lights on from 07:00 to 19:00) at 24 ± 1°C
and humidity of 60 ± 10% with food and water ad libi-
tum. They were synchronized to the lighting conditions
for two weeks before experiment. We prepared mouse
models of PSL under sodium pentobarbital (40 mg/kg, i.
p.) or diethyl ether anesthesia. The left thigh was shaved
and the sciatic nerve was exposed through an incision.
Half of the nerve was tightly ligated with 8-0 silk thread
and the wound was sutured. The left sciatic nerve was
exposed and then the wound was closed without ligation
in control, sham-operated mice. Animals were treated in
accordance with the guidelines stipulated by the animal
care and use committee of Kyushu University. Gabapen-
tin (Tokyo Chemical Industry Co. Ltd., Tokyo, Japan)
was dissolved in saline and injected i.p. in a volume of
0.1 mL/10 g body weight.
Assessment of tactile allodynia
Mechanical allodynia was assessed using a dynamic plan-
tar aesthesiometer (Ugo Basile, Varese, Italy), which is an
automated von Frey-type system. The mice were placed
in plastic cages with a wire mesh floor and allowed to
acclimate for 15 min before measuring hind paw
mechanical thresholds. A paw-flick response was elicited
by applying increasing force (in grams) using a metallic
filament focused on the middl eo ft h ep l a n t a rs u r f a c eo f
the hind paw. The applied force was initially below the
detection threshold, increased from 1 to 15 g in 0.5 g
steps over 20 sec, and then maintained at 15 g for an
additional 10 sec. The force applied to elicit a reflex
removal of the hind paw was monitored. To evaluate the
alleviation effects of gabapentin on tactile allodynia, the
AUC was calculated using the trapezoidal rule over the
entire time course of the PWT of the injured paw.
Determination of gabapentin concentration in serum
The serum concentration of gabapentin was measured
by high performance liquid chromatography (HPLC)
using DL-norvaline (Wako, Osaka, Japan) as the internal
standard. Gabapentin and DL-norvaline were derivatized
with o-phthaldialdehyde (OPA; Wako) as described [32].
The mobile phase of phosphate buffer (pH 3.0; 20 mM)-
acetonitrile (3:2, v/v) was eluted at 1.5 mL/min through
a5 C 18-MS-II column (4.6 × 150 mm; Nakalai Tesque,
Kyoto, Japan) using an LC-20AD (Shimadzu, Kyoto,
Japan), The separated analyte was detected using a Spec-
trofluorometric Detector RF-550 (excitation and emis-
sion at 330 and 450 nm, respectively; Shimadzu). The
total separation lasted 30 min, with DL-norvaline and
gabapentin eluting at 6 and 22 min, respectively.
Determination of gabapentin incorporation into DRG
T h eL 4 / L 5D R Gw e r ei s o l a t e df r o mP S Lm i c ea n dp r e -
incubated for 15 min at 4°C or 37°C with 1 mL of
Krebs-Henseleit buffer (118 mM NaCl, 4.8 mM KCl, 25
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1.2 mM MgSO4 7H2O, 11 mM glucose, 0.06 mM ascor-
bic acid, 0.03 mM disodium EDTA 2H2O) and equili-
brated with 95% O2 and 5% CO2. After pre-incubation
for 20 min, [
3H]-gabapentin (Muromachi Chemical Inc.,
Tokyo, Japan) was added to the incubation medium to a
final concentration of 25, 50, 100, and 500 μM. The seg-
ments were incubated for 30 min. After incubation, the
segments were rinsed three times with ice-cold PBS and
homogenized with CelLytic
™ MT Cell Lysis Reagent
(Sigma-Aldrich Company, Dorset, UK). The protein
concentration was determined in half volumes of homo-
genates using Lowry’s method (DC protein assay; Bio-
Rad, HercuIes, CA). The radioactivity in the other half
of the homogenate was solubilized and then determined
using a liquid scintillation counter. The amounts of
[
3H]-gabapentin incorporated into the DRG are
expressed as pmol/mg protein.
Ultrafiltration binding assays
The L4/L5 DRG removed from 14 mice was pooled to
obtain an adequate amount of protein and homogenized
in 0.1 mL of ice-cold CeILytic™MT Cell Lysis Reagent
(Sigma-Aldrich). The homogenate was then centrifuged
at 4,000 rpm for 3 min at 4°C and the protein concen-
tration was adjusted to 0.1 mg/mL. Binding was assayed
in the soluble fraction containing 25 μg of DRG protein,
and from 31 to 500 nM [
3H]-gabapentin. Nonspecific
binding was determined by adding a 100-fold excess of
non-radiolabeled gabapentin. The total drug concentra-
tion was measured after incubation at 37°C for 30 min
in 50 μL portions of each reaction mixture. A second
aliquot (450 μL) of the mixture was filtered through an
ultrafiltration membrane with a 50 kDa molecular
weight cut-off (Millipore, Bedford, MA, USA). The
amount of bound [
3H]-gabapentin was determined by
scintillation counting. Specific binding in the DRG was
estimated as the ratio of [
3H]-gabapentin drug concen-
trations in the ultrafiltrate and reaction mixture. Binding
parameters, affinity constants (Kd) and maximum bind-
ing capacity (Bmax; pmol/mg protein) were estimated
from three independent experiments.
Western Blotting
The L4/L5 DRG removed from PSL mice at 09:00,
13:00, 17:00, 21:00, 01:00 and 5:00 were homogenized in
CelLytic
™ MT Cell Lysis Reagent (Sigma-Aldrich). After
centrifugation at 12,000 g for 15 min, proteins in the
the supernatant (5 μg )w e r es e p a r a t e do ns o d i u md o d e -
cyl sulfate-polyacrylamide gels, and transferred to a
polyvinylidene difluoride membrane. The proteins on
the membrane were reacted with antibodies against the
a2δ-1 subunit (Alomone Labs, Jerusalem, Israel), or
ACTIN (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Specific antigen-antibody complexes were visua-
lized using horseradish peroxidase-conjugated secondary
antibodies and Chemi-Lumi One (Nakalai Tesque Inc.,
Kyoto, Japan).
RT-PCR
Levels of the a1A and a2δ-1 subunits, as well as of b-actin
mRNA were measured using real-time or semi-quantita-
tive RT-PCR. Total RNA was extracted from L4/L5 DRG
using RNAiso (Takara Bio Inc., Shiga, Japan) at the six
time points described above. Complementary DNA
(cDNA) was prepared via reverse transcription of total
RNA using a ReverTra Ace® qPCR RT kit (Toyobo, Osaka,
Japan). Diluted cDNA samples were analyzed by Real-time
PCR using THUNDERBIRDTM SYBR® qPCR Mix
(Toyobo) and the 7500 Real-time PCR system (Applied
Biosystems, Foster City, CA). The sequences of the for-
ward/reverse primers were as follows: a1A subunit, 5’-
GCGAAGGCGACGATGGGGAG-3’/5’-CTGTGGCCC





The 0.05 level of probability was taken as the criterion for
significance. The statistical significance of differences was
analyzed by ANOVA and Fisher’s PLSD test among multi-
ple groups and by Student’s t-test between pairs of groups.
Additional material
Additional file 1: Influence of dosing-time on sedation induced by
gabapentin. Gabapentin (100 mg/kg) or saline were administered i.p. at
17:00 or 05:00 on day 7 after nerve injury. Assessment of locomotor
activities was carried out for 4 hr post-injection using a photobeam
activity monitoring system (Chronobiology Kit; Stanford Software
Systems, California). Each value represents the mean with S.E.M. (n = 6).
Additional file 2: Temporal expression profile for L-amino acid
transpotor-1 (LAT1) mRNA in DRG of PSL mice. Each value represents
the mean with S.E.M. (n = 4-6).
Additional file 3: The amount of gabapentin binding in the DRG is
correlated with the protein levels of a2δ-1 subunit. Upper panel
shows the difference in the protein levels of a2δ-1 subunit in the lysates
prepared from DRG. Lower panel shows the amount of gabapentin
binding in the DRG lysates. Sample numbers correspond to that in upper
panel.
Aabbreviations
DRG: dorsal root ganglion; GABA: gamma-aminobutyric acid; NSAID: non-
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